Cabiralizumab (FPA 008) is an anti-CSF1R monoclonal antibody (MAb). Cabiralizumab enhances T cell infiltration and antitumor T cell immune responses. Cabiralizumab inhibits the activation of osteoclasts and blocks bone destruction, and can be used in the research of rheumatoid arthritis (RA). Cabiralizumab can combine with Nivolumab for lung cancer research.
CAS Number | 1613144-80-1 |
Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
Related CSF-1R (c-Fms) Products |
---|
Tinengotinib
Tinengotinib is a modulator of several protein kinases, such as Aurora kinase, VEGFR kinase, and CSF-1R, etc. Tinengotinib can be used in studies related to diseases mediated by abnormalities in these kinases. |
AMG-820
AMG-820 is an anti-colony stimulating factor 1 receptor (CSF1R) monoclonal antibody. |
CSF1R-IN-15
CSF1R-IN-15 is an inhibitor targeting CSF1R. |
Pimicotinib
Pimicotinib is a novel, orally bioavailable, highly selective small-molecule inhibitor of colony-stimulating factor 1 (CSF-1) with antitumor activity and less inhibitory effects on c-Kit and PDGFR. |
c-Fms-IN-14
c-Fms-IN-14 is a c-Fms inhibitor with an IC50 value of 4 nM. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.